Опыт применения эмицизумаба у пациента с повторным нарастанием титра ингибирующих антител после индукции иммунной толерантности с частичным ответом

1. Zozulya N.I., Kumskova M.A., Polyanskaya T.Yu., Svirin P.V., Mamaev A.N., Galstyan G.M. Hemophilia A. Clinical guidelines, 2018. P. 19. (In Russ.).

2. DiMichele D.M., Kroner B.L.; North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002;87(1):52–7. PMID: 11848456.

3. Haya S., Lopez M.F., Aznar J.A., Batlle J.; Spanish Immune Tolerance Group. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001;7(2):154–9. doi: 10.1046/j.1365-2516.2001.00469.x.

4. Lenk H.; ITT Study Group. The German Registry of immune tolerance treatment in hemophilia – 1999 update. Haematologica 2000;85(10 Suppl):45–7. PMID: 11187870.

5. Mariani G., Kroner B.; Immune Tolerance Study Group (ITSG). Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001;86(11):1186–93. PMID: 11694405.